All In Biotech

Drug Trial Radar · NCT07184385

A Study of Human Umbilical Cord Blood (REGENECYTE) Infusion in Patients With Post-COVID Condition

A Multicenter, Double-blind, Randomized, Placebo-controlled, Two-arm Phase III Study to Assess the Efficacy of Human Umbilical Cord Blood (REGENECYTE) Infusion in Reducing Fatigue in Post-COVID Condition

Last checked: Nov 20, 2026Latest source record: Sep 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Mar 31, 2026

Primary completion

Jun 30, 2027

Study completion Sep 30, 2027

Sponsor

Lead sponsor
StemCyte, Inc.Industry
Sponsor type
Industry
First posted
Sep 19, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

REGENECYTE (HPC, Cord Blood) for treatment in patients with post-COVID.

Conditions

  • Long COVID
  • Post-COVID-19 Condition
  • Post-COVID Syndrome
  • Post-COVID Condition

Interventions

  • REGENECYTEBiological

    HPC, Cord Blood

  • PlaceboBiological

    Normal Saline

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The change of efficacyTime frame: Week

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.